American Journal of Cardiovascular Drugs
Scope & Guideline
Exploring Innovations in Cardiovascular Therapy
Introduction
Aims and Scopes
- Pharmacotherapy for Cardiovascular Diseases:
The journal primarily emphasizes studies related to pharmacological treatments for various cardiovascular conditions, including heart failure, myocardial infarction, and arrhythmias. - Meta-analyses and Systematic Reviews:
A significant portion of the publications includes meta-analyses and systematic reviews that synthesize existing research to provide comprehensive insights into treatment efficacy and safety. - Real-World Evidence:
The journal publishes studies utilizing real-world data to assess the effectiveness and safety of cardiovascular drugs in everyday clinical practice, highlighting the practical implications of therapeutic choices. - Emerging Therapies and Novel Agents:
Research on new and emerging pharmacological agents for cardiovascular conditions is a key focus, showcasing advancements in drug development and innovative treatment strategies. - Guideline-Directed Therapy:
The journal emphasizes the importance of guideline-directed medical therapy, discussing strategies to optimize treatment adherence and improve patient outcomes.
Trending and Emerging
- SGLT2 Inhibitors and GLP-1 Receptor Agonists:
There is a marked increase in studies focusing on the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists, particularly in patients with heart failure and diabetes, showcasing their role in cardio-protection. - Real-World Data Analyses:
An emerging trend is the utilization of real-world data analyses to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights that complement randomized controlled trials. - Pharmacogenomics and Personalized Medicine:
Research into pharmacogenomics and its application in personalized medicine is gaining traction, highlighting the importance of tailoring cardiovascular therapies to individual patient characteristics. - Novel Antithrombotic Strategies:
There is a rising interest in novel antithrombotic strategies and combination therapies, particularly in the context of high-risk patients and those with complex comorbidities. - Health Economics and Cost-Effectiveness:
Increasingly, studies evaluating the cost-effectiveness of cardiovascular therapies are appearing, reflecting a growing emphasis on the economic implications of treatment choices in healthcare.
Declining or Waning
- Traditional Anticoagulation Strategies:
Research focusing on traditional anticoagulants, such as warfarin, is becoming less frequent as newer direct oral anticoagulants (DOACs) gain prominence in clinical practice. - Long-term Outcomes of Older Medications:
Studies examining the long-term outcomes of older medications such as digoxin and certain beta-blockers are declining, as the focus shifts toward newer agents with better efficacy and safety profiles. - Single-Agent Therapies:
There is a noticeable decrease in publications centered around single-agent therapies, as combination therapies and multifactorial approaches gain attention for their enhanced effectiveness.
Similar Journals
CIRCULATION
Shaping the Future of Cardiology Through Rigorous Research.CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.
Cardiology Journal
Empowering global research in cardiology.Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.
Cardiology in Review
Bridging research and practice in cardiology.Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.
Journal of Cardiovascular Emergencies
Empowering healthcare professionals with vital insights in cardiovascular emergencies.Journal of Cardiovascular Emergencies is a premier open-access journal dedicated to advancing the field of emergency cardiovascular care. Published by SCIENDO, the journal has been an essential resource for healthcare professionals since its inception in 2015, prioritizing the dissemination of cutting-edge research, case studies, and reviews that address acute cardiovascular conditions. With the ISSN 2457-5518 and E-ISSN 2457-550X, it stands as a valuable platform for researchers and practitioners alike, offering insights that can lead to improved patient outcomes in emergency settings. The journal, based in Warsaw, Poland, aims to foster collaboration and knowledge exchange within the growing community of cardiology and emergency medicine professionals. By making its content freely accessible, the Journal of Cardiovascular Emergencies underscores the importance of knowledge sharing in tackling the challenges presented by cardiovascular emergencies on a global scale.
VASCULAR PHARMACOLOGY
Elevating the standards of vascular pharmacological research.Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.
Netherlands Heart Journal
Pioneering Research in Cardiology and Cardiovascular MedicineNetherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.
Revista de la Federacion Argentina de Cardiologia
Fostering collaboration to enhance cardiovascular care.Revista de la Federacion Argentina de Cardiologia is a vital publication in the field of Cardiology and Cardiovascular Medicine, providing a platform for researchers and healthcare professionals to share significant findings and innovative concepts since its inception in 2012. Published by the Federacion Argentina Cardiology, this journal specifically addresses contemporary issues and advancements within cardiology, contributing to the scholarly dialogue essential for improving cardiovascular health. Despite being categorized in the Q4 quartile for 2023 and presently ranking #358 out of 387 in its field, the journal remains committed to fostering academic inquiry and disseminating valuable research for both local and global audiences. Although it is not an open-access journal, it strives to balance accessibility with rigorous academic standards, ensuring quality contributions that are critical for practitioners and students alike. The journal’s ongoing evaluation and adaptation in the ever-evolving landscape of cardiology underscore its importance in advancing cardiovascular science and practice.
Journal of Cardiology
Connecting researchers and clinicians in the fight against heart disease.Journal of Cardiology, published by ELSEVIER, stands as a prominent resource in the field of cardiology and cardiovascular medicine. With a rich history since its inception in 1987, this peer-reviewed journal aims to disseminate cutting-edge research that enhances the understanding and treatment of cardiovascular diseases. Its 2023 ranking places it in the Q2 category within its discipline, reflecting its significance and impact, as evidenced by a Scopus rank of #123 out of 387 journals, positioning it in the 68th percentile of its field. The journal is headquartered in Japan, providing a unique perspective on cardiological advances relevant not only to the Asian continent but also globally. Though it does not currently offer open access, the Journal of Cardiology remains a vital institutional resource for researchers, clinicians, and students seeking to push the boundaries of cardiovascular science and improve patient outcomes.
CARDIOVASCULAR DRUGS AND THERAPY
Elevating standards in cardiovascular drug therapy.CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.
Current Treatment Options in Cardiovascular Medicine
Empowering healthcare professionals with cutting-edge treatment options.Current Treatment Options in Cardiovascular Medicine is a leading journal dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by SpringerNature, this journal seeks to bridge the gap between clinical practice and research by providing comprehensive reviews, insightful analyses, and updates on the latest treatment modalities available for cardiovascular diseases. With an ISSN of 1092-8464 and an E-ISSN of 1534-3189, it displays a commitment to disseminating critical information to healthcare professionals and researchers globally. Despite its recent categorization in the Q3 quartile, the journal continues to maintain relevance with a Scopus rank of #246 in the field, reflecting its contribution to the ongoing discourse in cardiovascular care. The publication encompasses a broad spectrum of topics, from interventional cardiology to pharmacotherapy, supporting the journal's objective to enhance patient care through evidence-based treatment options. Researchers, professionals, and students will find Current Treatment Options in Cardiovascular Medicine an indispensable resource for staying at the forefront of cardiovascular innovations and applications.